Growth Capitalist (https://growthcapitalist.com/tag/biomed/page/20/)
DNA treatment delivery specialist Vical (VICL) announced that it has secured up to $50 million in an ATM (At the Market) transaction. The purchase price is the prevailing market price at the time of the Draw Down Notice. Stifel Nicolaus Weisel acted as the exclusive agent on the transaction. Placement Agent counsel was Latham & Watkins, and issuer counsel was Cooley. See the PlacementTracker Deal Summary.
Novelos Therapeutics (NVLT) announced that it has raised $2 million in a Unit (Common Stock and Warrant) transaction with Renova Group. The common stock was sold at $1.00 per share, an approximate 3% discount to the market price ($1.03) of NVLT at deal announcement. A series of 1 million 60-Month Warrants with an exercise price of $1.25 per share (21.36% premium) was issued to the investors in this transaction. The transaction closed on Nov. 05, 2012.
Cancer therapy developer MEI Pharma (MEIP) announced that it is raising $27.5 million in a Unit (Common Stock and Warrant) transaction with investors including
New Leaf Venture, Vivo Ventures, Baker Brothers Advisors, APT Pharmaceuticals and RA Capital Management. The common stock was sold at $0.50 per share, an approximate 28% premium to the market price ($0.39) of MEIP at deal announcement. A series of 38,504,060 60-Month Warrants with an exercise price of $0.52 per share (33.33% premium) was issued to the investors in this transaction. Stifel Nicolaus Weisel acted as the exclusive agent on the transaction. Issuer counsel was Morgan, Lewis & Bockius.
Hansen Medical (HNSN) announced that it has raised $10 million in a Common Stock transaction with investor Intuitive Surgical Operations. The common stock was sold at $1.89 per share, an approximate 4% premium to the market price ($1.81) of HNSN at deal announcement. The Placement Agent was not disclosed. The transaction closed on Oct. 29, 2012.
